Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $33.7 million.

  • Contineum Therapeutics' Change in Acquisitions & Divestments fell 2034.81% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $166.8 million, marking a year-over-year increase of 1636.58%. This contributed to the annual value of $157.2 million for FY2024, which is 10487.28% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Change in Acquisitions & Divestments of $33.7 million as of Q3 2025, which was down 2034.81% from $39.4 million recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Change in Acquisitions & Divestments peaked at $48.7 million during Q1 2025, and registered a low of $12.6 million during Q3 2023.
  • Moreover, its 3-year median value for Change in Acquisitions & Divestments was $33.7 million (2025), whereas its average is $32.3 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first soared by 23553.4% in 2024, then plummeted by 2034.81% in 2025.
  • Contineum Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $31.3 million in 2023, then soared by 44.03% to $45.1 million in 2024, then dropped by 25.37% to $33.7 million in 2025.
  • Its last three reported values are $33.7 million in Q3 2025, $39.4 million for Q2 2025, and $48.7 million during Q1 2025.